Market capitalization | $174.83m |
Enterprise Value | $-125.15m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.79 |
EV/Sales (TTM) EV/Sales | -134.57 |
P/S ratio (TTM) P/S ratio | 187.99 |
P/B ratio (TTM) P/B ratio | 0.56 |
Revenue (TTM) Revenue | $930.00k |
EBIT (operating result TTM) EBIT | $-82.61m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
7 Analysts have issued a Neoleukin Therapeutics Inc forecast:
7 Analysts have issued a Neoleukin Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 0.93 0.93 |
-
|
|
Gross Profit | -2.33 -2.33 |
29%
29%
|
|
EBITDA | -79 -79 |
48%
48%
|
EBIT (Operating Income) EBIT | -83 -83 |
45%
45%
|
Net Profit | -75 -75 |
107%
107%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Rachel McMinn |
Employees | 107 |
Founded | 2018 |
Website | www.neurogene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.